Wegovy vs. Zepbound
100% Online — No Office Visit Required
Wegovy and Zepbound are the two FDA-approved medications for chronic weight management. Wegovy contains semaglutide; Zepbound contains tirzepatide. Both require provider evaluation.
Zepbound (tirzepatide) has shown higher average weight loss in trials compared to Wegovy (semaglutide). Both are effective and provider-approved programs. The right choice depends on individual response, tolerability, and access.
Side-by-Side Comparison
| Feature | Wegovy (Semaglutide) | Zepbound (Tirzepatide) |
|---|---|---|
| Active ingredient | Semaglutide 2.4mg | Tirzepatide 5–15mg |
| Mechanism | GLP-1 agonist | Dual GLP-1/GIP agonist |
| Average weight loss | ~15% | ~20–22% |
| Dosing | Weekly injection | Weekly injection |
Common Questions
Is Zepbound new?
Yes — Zepbound was approved by the FDA in November 2023 for chronic weight management. Tirzepatide (Mounjaro) had been available for type 2 diabetes since 2022.
Ready to Get Started?
Complete a brief online intake. A licensed provider will review your information and determine if treatment is appropriate for you.
The information provided through the OakMD® website, assessments, product pages, checkout flows, communications, and related services is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
Medical Disclaimer: The information provided through the OakMD® website, assessments, product pages, checkout flows, communications, and related services is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
Prescription treatment, if any, is provided only after review by a US-licensed provider and only if clinically appropriate. Read the full Medical Disclaimer.